BTIG Research initiated coverage on Abivax SA with a new price target
$ABVX
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG Research initiated coverage of Abivax SA with a rating of Buy and set a new price target of $43.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/23/2025 | $71.00 | Equal-Weight → Overweight | Morgan Stanley |
| 3/20/2025 | $12.00 | Equal-Weight | Morgan Stanley |
| 12/4/2024 | $33.00 | Mkt Outperform | JMP Securities |
| 7/29/2024 | $48.00 | Buy | Laidlaw |
| 5/20/2024 | $43.00 | Buy | BTIG Research |
| 4/29/2024 | $42.00 | Overweight | Piper Sandler |
| 4/29/2024 | $50.00 | Buy | Guggenheim |
| 11/14/2023 | $15.00 | Equal-Weight | Morgan Stanley |
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces that the underwriters of its offering of 10,156,000 American Depositary Shares ("ADSs"), each representing one ordinary share, €0.01 nominal value per share (each an "Ordinary Share"), of the Company, in the United States (the "Offer
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares ("ADSs"), each representing one ordinary share, €0.01 nominal value per share (each an "Ordinary Share"), of the Company, in the United States at an offering price of $64.00 per
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. CEST. Trading of the ordinary shares of the Company was halted at the request of the Company on July 24, 2025 from 9:00 a.m. CEST in the context of the previously announced public offering by the
424B5 - Abivax S.A. (0001956827) (Filer)
6-K - Abivax S.A. (0001956827) (Filer)
FWP - Abivax S.A. (0001956827) (Subject)
Morgan Stanley upgraded Abivax SA from Equal-Weight to Overweight and set a new price target of $71.00
Morgan Stanley initiated coverage of Abivax SA with a rating of Equal-Weight and set a new price target of $12.00
JMP Securities initiated coverage of Abivax SA with a rating of Mkt Outperform and set a new price target of $33.00
Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 fina
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn
SC 13G/A - Abivax S.A. (0001956827) (Subject)
SC 13G - Abivax S.A. (0001956827) (Subject)
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis 50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials. Individually, the 50 mg dose demonstrated a placebo-adjusted remission rate of 19.3% (p<0.0001) in ABTECT-1 and a placebo-adjusted remission rate of 13.4% (p=0.0001) in ABTECT-2.50 mg once-daily dose of obefazimod met all key secondary endpoints demonstrating highly statistically significant and clinica